vTv Therapeutics announced that Chief Medical Officer Thomas Strack presented new research on hypoglycemia-related burdens among adults with type 1 diabetes using automated insulin delivery systems at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia. The study, commissioned by vTv and conducted by dQ&A Market Research, surveyed 674 adults with type 1 diabetes, of whom 429 were using automated insulin delivery systems. Among those AID users, 24% reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia. After accounting for overlap across segments and weighting for A1C, approximately 54% of adults with type 1 diabetes using an AID system were estimated to experience at least one of four hypoglycemia-related burden dimensions. The research supports vTv's cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator being evaluated as an adjunctive therapy to insulin for type 1 diabetes, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
vTv Therapeutics IncNew research on hypoglycemia burden in AID users supports vTv's cadisegliatin, a first-in-class oral glucokinase activator with FDA Breakthrough Therapy designation for type 1 diabetes.
